Liontrust Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Liontrust Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$126M	Buy	+808,900	New	+$104M	2.55%	13

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Liontrust Investment Partners's ALXN Position: Q4 2020 in Review

Liontrust Investment Partners opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2020: 808,900 shares worth $126M. The stake represents 2.55% of the portfolio and ranks #13 among its holdings.

825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Liontrust Investment Partners held 808,900 shares of Alexion Pharmaceuticals worth $126M as of Q4 2020.
Alexion Pharmaceuticals was a new Liontrust Investment Partners position in Q4 2020.
Alexion Pharmaceuticals made up 2.55% of Liontrust Investment Partners's portfolio in Q4 2020, its #13 holding.
825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Liontrust Investment Partners's 13F filing for Q4 2020, filed 10 Feb 2021.